{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T22:04:47Z","timestamp":1762034687339,"version":"build-2065373602"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1NU2GGH002046-01-00"],"award-info":[{"award-number":["1NU2GGH002046-01-00"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The World Health Organization recommends screening for the cryptococcal antigen (CrAg), a predictor of cryptococcal meningitis, among antiretroviral therapy (ART)\u2013na\u00efve people with HIV (PWH) with CD4 &amp;lt;100 cells\/mm3. CrAg positivity among ART-experienced PWH with viral load (VL) nonsuppression is not well established, yet high VLs are associated with cryptococcal meningitis independent of CD4 count. We compared the frequency and positivity yield of CrAg screening among ART-experienced PWH with VL nonsuppression and ART-na\u00efve PWH with CD4 &amp;lt;100 cells\/mm3 attending rural public health facilities in Uganda.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed routinely generated programmatic reports on cryptococcal disease screening from 104 health facilities in 8 rural districts of Uganda from January 2018 to July 2019. A lateral flow assay (IMMY CrAg) was used to screen for cryptococcal disease. PWH were eligible for CrAg screening if they were ART-na\u00efve with CD4 &amp;lt;100 cell\/mm3 or ART-experienced with an HIV VL &amp;gt;1000 copies\/mL after at least 6 months of ART. We used Pearson\u2019s chi-square test to compare the frequency and yield of CrAg screening.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 71\u2005860 ART-experienced PWH, 7210 (10.0%) were eligible for CrAg screening. Among 15\u2005417 ART-na\u00efve PWH, 5719 (37.1%) had a CD4 count measurement, of whom 937 (16.4%) were eligible for CrAg screening. The frequency of CrAg screening was 11.5% (830\/7210) among eligible ART-experienced PWH compared with 95.1% (891\/937) of eligible ART- na\u00efve PWH (P\u2005&amp;lt;\u2005.001). The CrAg positivity yield was 10.5% among eligible ART-experienced PWH compared with 13.8% among eligible ART-na\u00efve PWH (P\u2005=\u2005.035).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The low frequency and high positivity yield of CrAg screening among ART-experienced PWH with VL nonsuppression suggest a need for VL- directed CrAg screening in this population. Studies are needed to evaluate the cost-effectiveness and impact of CrAg screening and fluconazole prophylaxis on the outcomes of ART-experienced PWH with VL nonsuppression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofab010","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:55:07Z","timestamp":1610326507000},"source":"Crossref","is-referenced-by-count":3,"title":["Cryptococcal Antigen Screening Among Antiretroviral Therapy\u2013Experienced People With HIV With Viral Load Nonsuppression in Rural Uganda"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5852-9674","authenticated-orcid":false,"given":"Joseph Baruch","family":"Baluku","sequence":"first","affiliation":[{"name":"Directorate of Programs Mildmay Uganda, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallen","family":"Mugabe","sequence":"additional","affiliation":[{"name":"Directorate of Programs Mildmay Uganda, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shem","family":"Mwebaza","sequence":"additional","affiliation":[{"name":"Directorate of Programs Mildmay Uganda, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Nakaweesi","sequence":"additional","affiliation":[{"name":"Directorate of Programs Mildmay Uganda, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Senyimba","sequence":"additional","affiliation":[{"name":"Directorate of Programs Mildmay Uganda, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel Peter","family":"Opio","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, US centers for Disease Control and Prevention, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mukasa","sequence":"additional","affiliation":[{"name":"Directorate of Programs Mildmay Uganda, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"2021021217185474800_CIT0001","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021021217185474800_CIT0002","article-title":"Mortality from HIV-associated meningitis in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"In press","author":"Tenforde","journal-title":"J Int AIDS Soc"},{"key":"2021021217185474800_CIT0003","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofv046","article-title":"Cryptococcal antigenemia in immunocompromised human immunodeficiency virus patients in rural Tanzania: a preventable cause of early mortality","volume":"2","author":"Letang","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2021021217185474800_CIT0004","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/655143","article-title":"Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count &lt; or = 100 cells\/microL who start HIV therapy in resource-limited settings","volume":"51","author":"Meya","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2021021217185474800_CIT0005","doi-asserted-by":"crossref","first-page":"e0210105","DOI":"10.1371\/journal.pone.0210105","article-title":"Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: a cost-effectiveness modeling analysis","volume":"14","author":"Rajasingham","year":"2019","journal-title":"PLoS One"},{"key":"2021021217185474800_CIT0006","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12879-017-2325-9","article-title":"Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda","volume":"17","author":"Ramachandran","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2021021217185474800_CIT0007","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/cid\/cix1143","article-title":"CD4 cell count threshold for cryptococcal antigen screening of HIV-infected individuals: a systematic review and meta-analysis","volume":"66","author":"Ford","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021021217185474800_CIT0008","doi-asserted-by":"crossref","first-page":"e1006207","DOI":"10.1371\/journal.ppat.1006207","article-title":"Immune correlates of HIV-associated cryptococcal meningitis","volume":"13","author":"Tenforde","year":"2017","journal-title":"PLoS Pathog"},{"key":"2021021217185474800_CIT0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12879-020-4798-1","article-title":"Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells\/mm3","volume":"20","author":"Wykowski","year":"2020","journal-title":"BMC Infect Dis"},{"volume-title":"Guidelines for the Diagnosis, Prevention, and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children, March 2018","year":"2018","author":"World Health Organization","key":"2021021217185474800_CIT0010"},{"key":"2021021217185474800_CIT0011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s12879-020-05129-w","article-title":"Cryptococcal antigenemia and its predictors among HIV infected patients in resource limited settings: a systematic review","volume":"20","author":"Derbie","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2021021217185474800_CIT0012","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofw055","article-title":"Cryptococcal antigenemia in Nigerian patients with advanced human immunodeficiency virus: influence of antiretroviral therapy adherence","volume":"3","author":"Oladele","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2021021217185474800_CIT0013","first-page":"21","article-title":"Cryptococcus neoformans\u201d infection among human immunodeficiency virus patients on highly active antiretroviral therapy in Benin City, Nigeria","volume":"69","author":"Egbe","year":"2015","journal-title":"New Zealand J Medical Lab Sci"},{"key":"2021021217185474800_CIT0014","doi-asserted-by":"crossref","first-page":"e75585","DOI":"10.1371\/journal.pone.0075585","article-title":"Comparison of cryptococcal antigenemia between antiretroviral na\u00efve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia","volume":"8","author":"Beyene","year":"2013","journal-title":"PLoS One"},{"key":"2021021217185474800_CIT0015","doi-asserted-by":"crossref","first-page":"e58377","DOI":"10.1371\/journal.pone.0058377","article-title":"High prevalence of cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia","volume":"8","author":"Alemu","year":"2013","journal-title":"PLoS One"},{"journal-title":"Clin Infect Dis","article-title":"Cryptococcal antigenemia in human immunodeficiency virus antiretroviral therapy\u2013experienced Ugandans with virologic failure","author":"Mpoza","key":"2021021217185474800_CIT0016"},{"volume-title":"Advance HIV Disease Management Toolkit","year":"2019","author":"Ministry of Health","key":"2021021217185474800_CIT0017"},{"volume-title":"Consolidated Guidelines for Prevention and Treatment of HIV in Uganda","year":"2016","author":"Ministry of Health","key":"2021021217185474800_CIT0018"},{"volume-title":"Consolidated Guidelines for Prevention and Treatment of HIV in Uganda","year":"2018","author":"Ministry of Health","key":"2021021217185474800_CIT0019"},{"volume-title":"Uganda Health Care System","year":"2011","author":"Kamwesiga","key":"2021021217185474800_CIT0020"},{"key":"2021021217185474800_CIT0021","doi-asserted-by":"crossref","first-page":"e78609","DOI":"10.1371\/journal.pone.0078609","article-title":"Uganda\u2019s new national laboratory sample transport system: a successful model for improving access to diagnostic services for early infant HIV diagnosis and other programs","volume":"8","author":"Kiyaga","year":"2013","journal-title":"PLoS One"},{"key":"2021021217185474800_CIT0022","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1744-8603-7-25","article-title":"Scaling up antiretroviral therapy in Uganda: using supply chain management to appraise health systems strengthening","volume":"7","author":"Windisch","year":"2011","journal-title":"Global Health"},{"key":"2021021217185474800_CIT0023","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1748-5908-7-98","article-title":"Do guidelines influence the implementation of health programs? \u2014 Uganda\u2019s experience","volume":"7","author":"Nabyonga Orem","year":"2012","journal-title":"Implementation Sci"},{"key":"2021021217185474800_CIT0024","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00042560-200206010-00003","article-title":"Predictive value of HIV-1 viral load on risk for opportunistic infection","volume":"30","author":"Swindells","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021021217185474800_CIT0025","doi-asserted-by":"crossref","first-page":"e0206796","DOI":"10.1371\/journal.pone.0206796","article-title":"Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort","volume":"13","author":"Weissberg","year":"2018","journal-title":"PLoS One"},{"key":"2021021217185474800_CIT0026","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1097\/00002030-200109280-00012","article-title":"Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents","volume":"15","author":"Kaplan","year":"2001","journal-title":"AIDS"},{"key":"2021021217185474800_CIT0027","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofy122","article-title":"Detrimental outcomes of unmasking cryptococcal meningitis with recent ART initiation","volume":"5","author":"Rhein","year":"2018","journal-title":"Open Forum Infect Dis"},{"journal-title":"Clin Infect Dis","article-title":"Prevalence and sequelae of cryptococcal antigenemia in antiretroviral therapy\u2013experienced populations: an evaluation of reflex cryptococcal antigen screening in Botswana","author":"Hurt","key":"2021021217185474800_CIT0028"},{"key":"2021021217185474800_CIT0029","doi-asserted-by":"crossref","first-page":"d6884","DOI":"10.1136\/bmj.d6884","article-title":"CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study","volume":"343","author":"Kahn","year":"2011","journal-title":"BMJ"},{"key":"2021021217185474800_CIT0030","doi-asserted-by":"crossref","first-page":"e11722","DOI":"10.1097\/MD.0000000000011722","article-title":"A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda","volume":"97","author":"Lofgren","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2021021217185474800_CIT0031","doi-asserted-by":"crossref","first-page":"e0230453","DOI":"10.1371\/journal.pone.0230453","article-title":"Diagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screening","volume":"15","author":"Ndlovu","year":"2020","journal-title":"PLoS One"},{"key":"2021021217185474800_CIT0032","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1758-2652-15-15","article-title":"Prevalence and factors associated with cryptococcal antigenemia among severely immunosuppressed HIV-infected adults in Uganda: a cross-sectional study","volume":"15","author":"Oyella","year":"2012","journal-title":"J Int AIDS Soc"},{"key":"2021021217185474800_CIT0033","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/QAI.0000000000001894","article-title":"Reflexive laboratory-based cryptococcal antigen screening and preemptive fluconazole therapy for cryptococcal antigenemia in HIV-infected individuals with CD4 &lt;100 cells\/\u00b5L: a stepped-wedge, cluster-randomized trial","volume":"80","author":"Meya","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021021217185474800_CIT0034","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/QAI.0b013e3182926f95","article-title":"Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda","volume":"63","author":"Andama","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021021217185474800_CIT0035","doi-asserted-by":"crossref","first-page":"e0161830","DOI":"10.1371\/journal.pone.0161830","article-title":"Estimated prevalence of Cryptococcus antigenemia (CrAg) among HIV-Infected adults with advanced immunosuppression in Namibia justifies routine screening and preemptive treatment","volume":"11","author":"Sawadogo","year":"2016","journal-title":"PLoS One"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab010\/35474562\/ofab010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/2\/ofab010\/36247364\/ofab010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/2\/ofab010\/36247364\/ofab010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T01:43:37Z","timestamp":1613180617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab010\/6066583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab010","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2021,1,6]]},"article-number":"ofab010"}}